Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis
Dianthus Therapeutics (Nasdaq: DNTH) has scheduled a conference call and webcast for September 8, 2025 at 8:00 a.m. EDT to discuss results from their Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG).
The clinical-stage biotechnology company, focused on developing next-generation antibody complement therapeutics for severe autoimmune diseases, will host the event with a Q&A session for registered participants. Investors can access the webcast through the company's website, with a replay available afterward.
Dianthus Therapeutics (Nasdaq: DNTH) ha programmato una conference call e un webcast per il 8 settembre 2025 alle 8:00 EDT per illustrare i risultati del suo trial di Fase 2 MaGic su claseprubart (DNTH103) nella miastenia grave generalizzata (gMG).
La societ脿 biofarmaceutica in fase clinica, specializzata nello sviluppo di terapie anticomplemento di nuova generazione per malattie autoimmuni gravi, terr脿 l'evento con una sessione di domande e risposte riservata ai partecipanti registrati. Gli investitori potranno seguire il webcast sul sito web dell'azienda; la registrazione sar脿 disponibile in seguito.
Dianthus Therapeutics (Nasdaq: DNTH) ha programado una conferencia telef贸nica y un webcast para el 8 de septiembre de 2025 a las 8:00 a.m. EDT para comentar los resultados de su ensayo de Fase 2 MaGic con claseprubart (DNTH103) en la miastenia gravis generalizada (gMG).
La compa帽铆a biotecnol贸gica en fase cl铆nica, centrada en desarrollar terapias complementarias con anticuerpos de nueva generaci贸n para enfermedades autoinmunes graves, organizar谩 el evento e incluir谩 una sesi贸n de preguntas y respuestas para los participantes registrados. Los inversores podr谩n acceder al webcast desde la web de la empresa y habr谩 una grabaci贸n disponible posteriormente.
Dianthus Therapeutics (Nasdaq: DNTH)电� 2025雲� 9鞗� 8鞚� 鞓れ爠 8鞁�(EDT)鞐� 鞝勴檾須岇潣 氚� 鞗轨簮鞀ろ姼毳� 鞓堨爼頃橁碃 鞛堨溂氅�, 鞚茧皹頇� 欷戩 欷戩攴茧霠レ(gMG)鞐愳劀 韥措灅鞀ろ攧耄皵毳错姼(DNTH103)鞚� 2靸� MaGic 鞛勳儊 瓴瓣臣毳� 氚滍憸頃� 鞓堨爼鞛呺媹雼�.
欷戩 鞛愱皜氅挫棴歆堩櫂鞚� 鞙勴暅 彀劯雽� 頃泊 氤挫泊 旃橂鞝滊ゼ 臧滊皽頃樀鐢 鞛勳儊 雼硠鞚� 鞚� 靸濍獏瓿淀暀 須岇偓电� 霌彪 彀戈皜鞛愲ゼ 雽�靸侅溂搿� 歆堨潣鞚戨嫷 靹胳厴鞚� 韽暔頃� 頄夓偓毳� 歆勴枆頃╇媹雼�. 韴瀽鞛愲摛鞚� 須岇偓 鞗轨偓鞚错姼毳� 韱淀暣 鞗轨簮鞀ろ姼鞐� 鞝戩啀頃� 靾� 鞛堨溂氅�, 鞚错泟 雼れ嫓氤搓赴 雲鬼檾霃� 鞝滉车霅╇媹雼�.
Dianthus Therapeutics (Nasdaq: DNTH) a programm茅 une conf茅rence t茅l茅phonique et un webcast pour le 8 septembre 2025 脿 8h00 EDT afin de pr茅senter les r茅sultats de son essai de phase 2 MaGic concernant le claseprubart (DNTH103) dans la myasth茅nie grave g茅n茅ralis茅e (gMG).
La soci茅t茅 biotechnologique en phase clinique, sp茅cialis茅e dans le d茅veloppement de th茅rapies compl茅mentaires par anticorps de nouvelle g茅n茅ration pour les maladies auto鈥慽mmunes s茅v猫res, organisera l'茅v茅nement avec une session de questions鈥憆茅ponses r茅serv茅e aux participants inscrits. Les investisseurs pourront acc茅der au webcast via le site web de la soci茅t茅; un replay sera disponible par la suite.
Dianthus Therapeutics (Nasdaq: DNTH) hat eine Telefonkonferenz und ein Webcast f眉r den 8. September 2025 um 8:00 Uhr EDT angesetzt, um die Ergebnisse der Phase鈥�2 MaGic鈥慡tudie von claseprubart (DNTH103) bei generalisierter Myasthenia gravis (gMG) zu besprechen.
Das klinische Biotechnologie鈥慤nternehmen, das sich auf die Entwicklung neuartiger Antik枚rper鈥慘omplement鈥慣herapien f眉r schwere Autoimmunerkrankungen spezialisiert hat, wird die Veranstaltung mit einer Fragerunde f眉r registrierte Teilnehmer abhalten. Aktion盲re k枚nnen das Webcast 眉ber die Unternehmenswebsite verfolgen; eine Aufzeichnung wird im Anschluss verf眉gbar sein.
- None.
- None.
NEW YORK and WALTHAM, Mass., Sept. 07, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced a conference call and webcast to discuss results from the Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG) scheduled for tomorrow, Monday, September 8, 2025 at 8:00 a.m. EDT.
Investor Webcast & Conference Call Information
To access the live conference call by phone, please register聽.听Conference call participants in the question and answer session should pre-register to receive the dial-in number and personal PIN.听
A live webcast may be accessed through the Investors and Media section of the Company鈥檚 website,聽. Following the call, a replay will be available at the same location.
About Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
To learn more, please visit and follow us on .听
Contact
Jennifer Davis Ruff
Dianthus Therapeutics
FAQ
When will Dianthus Therapeutics (DNTH) announce Phase 2 MaGic trial results for claseprubart?
How can investors access Dianthus Therapeutics' Phase 2 trial results conference call?
What is claseprubart (DNTH103) being developed for by Dianthus Therapeutics?
Will there be a replay available of Dianthus Therapeutics' Phase 2 trial results presentation?
